DiaGenic To Provide MCI Biomarkers For Merz Pharmaceuticals (Topix)
DiaGenic ASA today announced that it has signed an option agreement with Merz Pharmaceuticals GmbH, an innovative developer of drugs for treatment of illnesses in neurology and psychiatry, to gain access to biomarkers for Mild Cognitive Impairment , increasingly considered a transitional stage to Alzheimer's disease.
More... (From Topix Neurology) |
All times are GMT -5. The time now is 12:30 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.